Acurx Pharmaceuticals (ACXP) is scheduled to report Q1 earnings on May 12, 2026. Analysts estimate EPS of $-0.63 and quarterly revenue of N/A.
In the most recent quarter (Q4), Acurx Pharmaceuticals reported EPS of $-0.73, beating estimates of $-1.00 by 0.27%. Revenue came in at $0.00, meeting the estimate of $0.00 by 0.00%.
Acurx Pharmaceuticals has beaten EPS estimates in 6 consecutive quarters.
Over the last 4 quarters, Acurx Pharmaceuticals has averaged an EPS surprise of 0.29% and a revenue surprise of 0.00%.
Analyze the earnings history of Acurx Pharmaceuticals using advanced sorting and filters.
The chart below shows Acurx Pharmaceuticals's reported EPS compared to analyst estimates over recent quarters.
The chart below shows Acurx Pharmaceuticals's reported revenue compared to analyst estimates over recent quarters.
Acurx Pharmaceuticals (ACXP) is scheduled to report earnings on May 12, 2026. The last reported earnings were for reported on March 13, 2026 for Q4.
The Actual EPS was $-0.73, which beat the estimate of $-1.00.
The Actual Revenue was $0.00, which hit the estimate of $0.00.
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q4 | 2026-03-13 | $-0.73 | $-1.00 | 27.0 % |
| Q3 | 2025-11-12 | $-1.23 | $-1.54 | 20.1 % |
| Q2 | 2025-08-12 | $-1.89 | $-2.06 | 8.25 % |
| Q1 | 2025-05-13 | $-2.20 | $-5.80 | 62.1 % |